Peptide sources & regulatory information
Read each source in its original context. US approval or research does not establish UAE approval of a product, indication or formulation.
- 01NHGRI: what is a peptide? ↗
A peptide is a short chain of amino acids. This definition does not establish a treatment benefit.
- 02FDA: understanding compounded drugs ↗
Compounded medicines are not FDA-approved. FDA does not assess their safety, effectiveness or quality before marketing.
- 03FDA: substance-specific safety concerns ↗
Compound-specific concerns and evidence gaps. Read the exact substance and route; similarly named compounds are not interchangeable.
- 04EDE: pharmaceutical marketing authorization requirements ↗
General requirements for pharmaceutical product authorization in the UAE. This source does not establish authorization of any preparation in this collection.
- 05DHA: telehealth standards, version 4 ↗
Dubai Health Authority standards for healthcare professionals and facilities providing telehealth services.
- 06DarDoc: published clinical and pharmacy details ↗
DarDoc identifies its digital clinic (license 2985077) and DARDOC HEALTH PHARMACY LLC. Facility licensing does not establish product approval.
- 07FDA: EGRIFTA WR prescribing information ↗
The label applies to branded EGRIFTA WR, its indication and formulation. It does not approve the tesamorelin presentations in this catalog.
- 08DailyMed: VYLEESI prescribing information ↗
The label applies to VYLEESI. It does not establish equivalence or approval for the listed PT-141 pens, vials or nasal spray.
- 09FDA: FORZINITY trial and approval context ↗
FORZINITY approval concerns Barth syndrome. It does not establish approval of this SS-31 presentation or healthy-aging use.
- 10DoH: regenerative medicine and peptide requirements ↗
Abu Dhabi’s standard includes peptide-specific restrictions. It does not authorize any preparation listed here or grant this website advertising approval.
- 11FDA: choosing an online pharmacy ↗
Patient guidance on prescriptions, pharmacy credentials and warning signs of unsafe sellers. Its US licensing rules are not UAE rules or verification of a DarDoc supplier.
- 13FDA: questions to ask your pharmacist ↗
Practical questions about use, storage, side effects, monitoring and when to contact a clinician. Individual instructions must come from the prescribing and dispensing team.
- 14FDA: medicines and interactions ↗
Medicines, supplements and existing conditions can affect treatment safety. This is general guidance, not an interaction check for this catalog.
- 15USADA: BPC-157 and anti-doping considerations ↗
BPC-157 is prohibited in sports under the WADA list. Athletes should check each proposed treatment with their anti-doping organization; a prescription alone does not grant permission.
- 16DHA: MOHAP Decree No. 228 of 2023 on compounding requirements ↗
DHA circulates MOHAP technical and health provisions for compounding. This regulatory source is not verification of a particular facility or product approval.
- 17DarDoc Fitness: service information ↗
A provider’s service page is not independent evidence of preparation-specific quality tests, lawful supply or product authorization.
- 18DNA Health: physician consultation and ongoing care ↗
An example of another clinical provider publishing physician consultation and ongoing follow-up. Provider services and sourcing vary.
- 19EDE: licensed pharmaceutical facilities in the UAE ↗
EDE provides a service to request records of licensed pharmaceutical facilities. The service page does not establish any individual lab’s license or scope.
Sources checked September 15, 2026. Regulatory information may change.